Response

The manufacturer has established a robust body of clinical evidence that demonstrates the safety, performance, and clinical benefit of the device, providing sufficient clinical evidence in both quantity and quality in accordance with Article 61 and Annex XIV of the Regulation (EU) 2017/745.

In terms of quantity, the body of clinical evidence is derived from nine clinical investigations involving over 800 patients. This portfolio includes eight pivotal clinical investigations conducted with the current version of the device and one clinical investigation conducted with the equivalent legacy version. The cumulative dataset covers a broad range of dermatological conditions, user tiers (primary care practitioners and dermatologists), and clinical settings (prospective and retrospective), ensuring a statistically significant validation of the clinical performance and safety endpoints.

Regarding the quality of the data, all pivotal investigations were designed and conducted following methodologically sound procedures. The studies provide high-quality clinical data (Level 1 and 2 according to the hierarchy of clinical evidence) that consistently meet or exceed the predefined acceptance criteria. The clinical investigations were registered in public databases (ClinicalTrials.gov and EMA RWD Catalogue) and, where applicable, results have been published in peer-reviewed scientific literature.

The sufficiency of the clinical evidence regarding the intended patient population is supported by a comprehensive demographic analysis of the enrolled subjects. The study populations are representative of the target population across all life stages, including pediatric (6.3%), adult (69.5%), and geriatric (19.6%) populations, with a balanced gender distribution (45.4% male and 54.6% female). Furthermore, the investigations included patients across diverse skin pigmentations (Fitzpatrick phototypes I to V), reflecting the demographics of the intended clinical environment. While darker skin types (Phototype V and VI) represent a minority in the current dataset, this has been identified as a specific monitoring priority in the post-market clinical follow-up plan.

The coverage of clinical indications is justified through the validation of the device's performance across "anchor" conditions that represent the highest clinical risks and the most common diagnostic challenges. These include malignancy detection (melanoma, basal cell carcinoma, and squamous cell carcinoma), chronic inflammatory diseases (psoriasis, hidradenitis suppurativa, and acne), and rare dermatological conditions. The core algorithmic architecture of the device (Vision Transformer) ensures that the technical capability to process and interpret clinical signs from image pixels is consistent across different pathologies. Validating this core capability on high-risk and representative conditions provides a high level of confidence in the device's performance across the broader category of conditions affecting the skin and its appendages.

The clinical performance of the device—which directly underpins its clinical benefits—has been empirically proven against performance thresholds derived from the generally acknowledged state of the art (SotA). Comparative analysis demonstrates that the device achieves its intended performance under normal conditions of use, substantiating measurable clinical benefits such as a 15% improvement in diagnostic accuracy for primary care practitioners, a 50% reduction in average waiting times in specific clinical workflows, and a 30% reduction in unnecessary specialist referrals.

Finally, the safety of the device is confirmed by the absence of serious adverse events or device-related complications across all clinical investigations. This is further supported by the extensive market experience of the equivalent legacy device, which has been in clinical use since 2020 with over 100,000 generated reports and zero reported serious incidents or vigilance notifications. This long-term safety profile, combined with the proactive post-market clinical follow-up activities, provides sufficient assurance that the clinical benefits of the device outweigh the identified residual risks.

In conclusion, the manufacturer has provided a robust justification, supported by high-quality clinical data and extensive market experience, that sufficient evidence has been analyzed to confirm the clinical benefit, safety, and performance of the device for all relevant populations and indications.

For further details, please refer to the updated Clinical Evaluation Report (R-TF-015-003, Section 15.4) and the Clinical Evaluation Plan (R-TF-015-001, Section 11), which have been updated to include the comprehensive population coverage analysis and the integrated evidence synthesis.